# A Study of LY3305677 in Participants With Obesity Or Overweight

> **NCT05623839** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** LY3305677
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05623839
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-16
- **Primary completion:** 2023-06-27
- **Final completion:** 2023-06-27
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623839, "A Study of LY3305677 in Participants With Obesity Or Overweight". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05623839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*